Download video

65. Pseudoprogression and pseudoresponse; post treatment glioma MRI, RANO, Stupp, Bevacizumab, rCBV

710 views

Brain - Bit by Bit (neuroradiology)

9 months ago

65. Pseudoprogression and pseudoresponse; post treatment glioma MRI, RANO, Stupp, Bevacizumab, rCBV

65. Pseudoprogression and pseudoresponse; post treatment glioma MRI, RANO, Stupp, Bevacizumab, rCBV

65. Pseudoprogression and pseudoresponse; post treatment glioma MRI, RANO, Stupp, Bevacizumab, rCBV
7:06
65. Pseudoprogression and pseudoresponse; post treatment glioma MRI, RANO, Stupp, Bevacizumab, rCBV
by Brain - Bit by Bit (neuroradiology)
Assessment of Post Treatment Glioma Response With Brain Tumor Reporting and Date System (BT-RADS)
15:09
Assessment of Post Treatment Glioma Response With Brain Tumor Reporting and Date System (BT-RADS)
by PCO Professional Academy
Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors
0:52
Evaluating JZP898, an IFN-α and pembrolizumab in advanced solid tumors
by VJOncology
Prognostic evaluation of re-resection in recurrent glioblastoma: RANO classification report
4:29
Prognostic evaluation of re-resection in recurrent glioblastoma: RANO classification report
by VJOncology
Dr. Mark Gilbert Discusses Frontline Bevacizumab in Glioblastoma
4:26
Dr. Mark Gilbert Discusses Frontline Bevacizumab in Glioblastoma
by Targeted Oncology
MERIT Webinar: Understanding Pseudoprogression - Navigating Neuro-Oncology
57:38
MERIT Webinar: Understanding Pseudoprogression - Navigating Neuro-Oncology
by MERIT CRO
Brain Tumor Webinar
1:11:11
Brain Tumor Webinar
by musellafoundation
Mr Ananda Dhanasekaran Discusses Suction Cystoscopes in Endourology: A Game Changer
7:26
Mr Ananda Dhanasekaran Discusses Suction Cystoscopes in Endourology: A Game Changer
by CJ Medical
Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
1:42
Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
by Targeted Oncology
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
0:57
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
by VJOncology
Gene Mutations as Predictive Biomarkers for Cisplatin-Based Chemotherapy Response in Bladder Cancer
8:08
Gene Mutations as Predictive Biomarkers for Cisplatin-Based Chemotherapy Response in Bladder Cancer
by GU Oncology Now
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
1:21
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas
by Targeted Oncology
AMBASSADOR: extended DFS follow-up of adjuvant pembrolizumab in MIUC
1:33
AMBASSADOR: extended DFS follow-up of adjuvant pembrolizumab in MIUC
by VJOncology
Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
5:23
Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
by PracticeUpdate
CHECKMATE 205: factors associated with PFS in patients with R\/R HL treated with nivolumab
1:28
CHECKMATE 205: factors associated with PFS in patients with R\/R HL treated with nivolumab
by VJHemOnc – Video Journal of Hematology \& HemOnc
HRQoL in KEYNOTE-966: pembrolizumab with gemcitabine and cisplatin for advanced biliary tract cancer
1:14
HRQoL in KEYNOTE-966: pembrolizumab with gemcitabine and cisplatin for advanced biliary tract cancer
by VJOncology
Analyzing New Data from KEYNOTE-427 in Patients With RCC
1:17
Analyzing New Data from KEYNOTE-427 in Patients With RCC
by Targeted Oncology